Tolerabilities of Antiretrovirals in Paediatric HIV Infection

[1]  C. Giaquinto,et al.  Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial , 2002, The Lancet.

[2]  O. Naderer,et al.  Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. , 2001, Clinical therapeutics.

[3]  C. Perry,et al.  Nevirapine: a review of its use in the prevention and treatment of paediatric HIV infection. , 2000, Paediatric drugs.

[4]  H. Chambost,et al.  Relationship between efficacy, tolerance, and plasma drug concentration of ritonavir in children with advanced HIV infection. , 2000, Therapeutic drug monitoring.

[5]  C. Perry,et al.  Abacavir , 2000, Drugs.

[6]  K. Miller,et al.  Lactic Acidosis and Hepatic Steatosis Associated with Use of Stavudine: Report of Four Cases , 2000, Annals of Internal Medicine.

[7]  P. Pezzotti,et al.  Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian Register for HIV Infection in Children and the Italian National AIDS Registry. , 2000, JAMA.

[8]  W. Hop,et al.  Clinical and virologic response to combination treatment with indinavir, zidovudine, and lamivudine in children with human immunodeficiency virus-1 infection: a multicenter study in the Netherlands. On behalf of the Dutch Study Group for Children with HIV-1 infections. , 2000, The Journal of pediatrics.

[9]  C. Fletcher,et al.  Pharmacologic Characteristics of Indinavir, Didanosine, and Stavudine in Human Immunodeficiency Virus-Infected Children Receiving Combination Therapy , 2000, Antimicrobial Agents and Chemotherapy.

[10]  M. Bassetti,et al.  Indinavir Pharmacokinetics and Parmacodynamics in Children with Human Immunodeficiency Virus Infection , 2000, Antimicrobial Agents and Chemotherapy.

[11]  G. Mieli-Vergani,et al.  A Dose Ranging Study of the Pharmacokinetics, Safety, and Preliminary Efficacy of Lamivudine in Children and Adolescents with Chronic Hepatitis B , 2000, Antimicrobial Agents and Chemotherapy.

[12]  C. Fortuny,et al.  Rash as side-effect of nelfinavir in children. , 2000, AIDS.

[13]  J. Sass,et al.  Paronychia with Pyogenic Granuloma in a Child Treated with Indinavir: The Retinoid-Mediated Side Effect Theory Revisited , 2000, Dermatology.

[14]  M. Gersten,et al.  Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team. , 1999, The New England journal of medicine.

[15]  C. Perry,et al.  Didanosine , 1999, Drugs.

[16]  D. Kotler,et al.  Visceral obesity, hypertriglyceridemia and hypercortisolism in a boy with perinatally acquired HIV infection receiving protease inhibitor-containing antiviral treatment. , 1999, AIDS.

[17]  P. Rustin,et al.  Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues , 1999, The Lancet.

[18]  W. Kreuz,et al.  Preliminary experiences with triple therapy including nelfinavir and two reverse transcriptase inhibitors in previously untreated HIV-infected children. , 1999, AIDS.

[19]  S M Marcovina,et al.  Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. , 1999, Circulation.

[20]  Kessler,et al.  Bleeding episodes in HIV‐positive patients taking HIV protease inhibitors: a case series , 1999, Haemophilia : the official journal of the World Federation of Hemophilia.

[21]  G. Chittick,et al.  Single-Dose Pharmacokinetics and Safety of Abacavir (1592U89), Zidovudine, and Lamivudine Administered Alone and in Combination in Adults with Human Immunodeficiency Virus Infection , 1999, Antimicrobial Agents and Chemotherapy.

[22]  G. E. Pakes,et al.  Lamivudine/Zidovudine as a Combined Formulation Tablet: Bioequivalence Compared with Lamivudine and Zidovudine Administered Concurrently and the Effect of Food on Absorption , 1999, Journal of clinical pharmacology.

[23]  J. Murray,et al.  Unusual distributions of body fat in AIDS patients: a review of adverse events reported to the Food and Drug Administration. , 1999, AIDS patient care and STDs.

[24]  M. Gersten,et al.  Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  J. Lindsey,et al.  Combination Therapy With Stavudine (d4T) Plus Didanosine (ddI) in Children With Human Immunodeficiency Virus Infection , 1999, Pediatrics.

[26]  F. Babl,et al.  Abnormal body-fat distribution in HIV-1-infected children on antiretrovirals , 1999, The Lancet.

[27]  C. Fletcher,et al.  A Phase I Study of Abacavir (1592U89) Alone and in Combination With Other Antiretroviral Agents in Infants and Children With Human Immunodeficiency Virus Infection , 1999, Pediatrics.

[28]  L. Mofenson,et al.  A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). , 1999, AIDS.

[29]  R. Yogev,et al.  Safety and Single-Dose Pharmacokinetics of Abacavir (1592U89) in Human Immunodeficiency Virus Type 1-Infected Children , 1999, Antimicrobial Agents and Chemotherapy.

[30]  C. Collantes,et al.  Severe paronychia due to zidovudine-induced neutropenia in a neonate. , 1999, Journal of the American Academy of Dermatology.

[31]  H. Chambost,et al.  Combination antiretroviral therapy including ritonavir in children infected with human immunodeficiency. , 1999, AIDS.

[32]  K. Melbourne,et al.  Characterization of Rash with Indinavir in a National Patient Cohort , 1999, The Annals of pharmacotherapy.

[33]  J. Leonard,et al.  Pharmacokinetic Interaction between Ritonavir and Indinavir in Healthy Volunteers , 1998, Antimicrobial Agents and Chemotherapy.

[34]  R. Pollard,et al.  Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. , 1998, Clinical therapeutics.

[35]  D. Ascher,et al.  Spontaneous bleeding associated with the use of the protease inhibitor ritonavir in a hemophiliac patient with human immunodeficiency virus infection. , 1998, The Pediatric infectious disease journal.

[36]  M. Youle,et al.  Safety, Pharmacokinetics, and Antiretroviral Activity of the Potent, Specific Human Immunodeficiency Virus Protease Inhibitor Nelfinavir: Results of a Phase I/II Trial and Extended Follow‐up in Patients Infected with Human Immunodeficiency Virus , 1998, Journal of clinical pharmacology.

[37]  S. Spector,et al.  Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. , 1998, The Journal of infectious diseases.

[38]  P. Pizzo,et al.  Pediatric AIDS : the challenge of HIV infection in infants, children, and adolescents , 1998 .

[39]  S. Steinberg,et al.  A Phase I/II Study of the Protease Inhibitor Indinavir in Children With HIV Infection , 1998, Pediatrics.

[40]  D. Faulds,et al.  Nelfinavir. A review of its therapeutic efficacy in HIV infection. , 1998, Drugs.

[41]  H. Jürgens,et al.  Platelet Dysfunction as the Cause of Spontaneous Bleeding in Two Haemophilic Patients Taking HIV Protease Inhibitors , 1998, Thrombosis and Haemostasis.

[42]  J. J. Henning,et al.  Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000 , 1998, HIV clinical trials.

[43]  V. Wahn,et al.  Pilot study of zidovudine–lamivudine combination therapy in vertically HIV‐infected antiretroviral‐naive children , 1998, AIDS.

[44]  S. Steinberg,et al.  A Phase I/II Study of the Protease Inhibitor Ritonavir in Children With Human Immunodeficiency Virus Infection , 1998, Pediatrics.

[45]  J. Lindsey,et al.  A randomized comparative trial of stavudine (d4T) versus zidovudine (ZDV, AZT) in children with human immunodeficiency virus infection. AIDS Clinical Trials Group 240 Team. , 1998, Pediatrics.

[46]  L. Anderson,et al.  Transplacental effects of 3'-azido-2',3'-dideoxythymidine (AZT): tumorigenicity in mice and genotoxicity in mice and monkeys. , 1997, Journal of the National Cancer Institute.

[47]  D. Ascher,et al.  Indinavir Sulfate Renal Toxicity in a Pediatric Hemophiliac with HIV Infection , 1997, The Annals of pharmacotherapy.

[48]  B. Rudy,et al.  Protease inhibitor therapy in children with perinatally acquired HIV infection , 1997, AIDS.

[49]  L. Frenkel,et al.  Clinical, virologic and immunologic responses of children with advanced human immunodeficiency virus type 1 disease treated with protease inhibitors. , 1997, The Pediatric infectious disease journal.

[50]  R. McKinnis,et al.  A comparative trial of zidovudine administered every four versus every twelve hours for the treatment of advanced HIV disease. , 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[51]  S. Spector,et al.  Comparative trial of two dosages of zalcitabine in zidovudine-experienced children with advanced human immunodeficiency virus disease. Pediatric AIDS Clinical Trials Group. , 1997, The Pediatric Infectious Disease Journal.

[52]  L. Mofenson,et al.  Evaluation of pharmacokinetics, safety, tolerance, and activity of combination of zalcitabine and zidovudine in stable, zidovudine-treated pediatric patients with human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 190 Team. , 1997, The Journal of infectious diseases.

[53]  J. Sullivan,et al.  Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children. , 1996, The Journal of infectious diseases.

[54]  J. Darbyshire,et al.  Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals , 1996, The Lancet.

[55]  J. Church,et al.  Lamivudine in children with human immunodeficiency virus infection: a phase I/II study. The National Cancer Institute Pediatric Branch-Human Immunodeficiency Virus Working Group. , 1996, The Journal of infectious diseases.

[56]  L. Steinherz.  Cardiomyopathy related to acquired immunodeficiency syndrome in children. , 1996, The Journal of pediatrics.

[57]  R. Gelber,et al.  Randomized study of the tolerance and efficacy of high- versus low-dose zidovudine in human immunodeficiency virus-infected children with mild to moderate symptoms (AIDS Clinical Trials Group 128). Pediatric AIDS Clinical Trials Group. , 1996, The Journal of infectious diseases.

[58]  M. Hirsch,et al.  Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro. , 1996, The Journal of infectious diseases.

[59]  K. Williams,et al.  Phase I evaluation of zalcitabine administered to human immunodeficiency virus-infected children. , 1995, The Journal of infectious diseases.

[60]  J. Church,et al.  A phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection. , 1995, Pediatrics.

[61]  M. Domanski,et al.  Effect of zidovudine and didanosine treatment on heart function in children infected with human immunodeficiency virus. , 1995, The Journal of pediatrics.

[62]  V. Anderson,et al.  Pancreatic disorders in pediatric acquired immune deficiency syndrome. , 1995, Human pathology.

[63]  D. Gibb,et al.  A Risk-Benefit Assessment of Zidovudine in the Prevention of Perinatal HIV Transmission , 1995, Drug safety.

[64]  N. Brousse,et al.  Hepatic Toxicity Associated with 2′-3'Dideoxyinosine in Children with AIDS , 1995, Journal of pediatric gastroenterology and nutrition.

[65]  D. Richman,et al.  The tolerance for zidovudine plus thrice weekly or daily trimethoprim-sulfamethoxazole with and without leucovorin for primary prophylaxis in advanced HIV disease. California Collaborative Treatment Group. , 1995, The American journal of medicine.

[66]  M. Brouillette,et al.  Didanosine-induced mania in HIV infection. , 1994, The American journal of psychiatry.

[67]  R. Gelber,et al.  Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. , 1994, The New England journal of medicine.

[68]  D. Venzon,et al.  Clinical and pharmacokinetic evaluation of long-term therapy with didanosine in children with HIV infection. , 1994, Pediatrics.

[69]  P. Pizzo,et al.  Antiretroviral therapy for infection due to human immunodeficiency virus in children. , 1994, Pediatric AIDS and HIV infection.

[70]  C. Rouzioux,et al.  Randomized study of two doses of didanosine in children infected with human immunodeficiency virus. , 1993, The Journal of pediatrics.

[71]  D. Venzon,et al.  Pancreatitis in human immunodeficiency virus-infected children receiving dideoxyinosine. , 1993, Pediatrics.

[72]  J. Lipsky.  Zalcitabine and didanosine , 1993, The Lancet.

[73]  S. Colan,et al.  Cardiac structure and function in children with human immunodeficiency virus infection treated with zidovudine. , 1992, The New England journal of medicine.

[74]  P. Vanhems,et al.  Extreme elevations of serum lactic dehydrogenase differentiating pulmonary toxoplasmosis from Pneumocystis pneumonia. , 1992, The New England journal of medicine.

[75]  A. Pesce,et al.  Concentrations of Phosphorylated Zidovudine (ZDV) in Patient Leukocytes Do Not Correlate with ZDV Dose or Plasma Concentrations , 1991, Therapeutic drug monitoring.

[76]  E. Walter,et al.  Myopathy in human immunodeficiency virus-infected children receiving long-term zidovudine therapy. , 1991, The Journal of pediatrics.

[77]  M. Wulfsohn,et al.  A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease. The Protocol 043 Study Group. , 1991, The New England journal of medicine.

[78]  R. McKinney.  Antiviral therapy for human immunodeficiency virus infection in children. , 1991, Pediatric clinics of North America.

[79]  D. Venzon,et al.  Dideoxyinosine in children with symptomatic human immunodeficiency virus infection , 1991 .

[80]  J. Falloon,et al.  Dideoxycytidine alone and in an alternating schedule with zidovudine in children with symptomatic human immunodeficiency virus infection. , 1990, The Journal of pediatrics.

[81]  A. Keller,et al.  Zidovudine (AZT) therapy in children with HIV infection: the Australian experience , 1990, Journal of paediatrics and child health.

[82]  P. Pizzo.  Treatment of human immunodeficiency virus-infected infants and young children with dideoxynucleosides. , 1990, The American journal of medicine.

[83]  W. Parks,et al.  Safety and tolerance of intermittent intravenous and oral zidovudine therapy in human immunodeficiency virus-infected pediatric patients. Pediatric Zidovudine Phase I Study Group. , 1990, The Journal of pediatrics.

[84]  H. Mitsuya,et al.  Clinical pharmacology of 3'-azido-2',3'-dideoxythymidine (zidovudine) and related dideoxynucleosides. , 1989, The New England journal of medicine.

[85]  J. Falloon,et al.  Pharmacokinetics of zidovudine administered intravenously and orally in children with human immunodeficiency virus infection. , 1989, The Journal of pediatrics.

[86]  J. Falloon,et al.  The pharmacokinetics of zidovudine administered by continuous infusion in children. , 1989, Annals of internal medicine.

[87]  R. Nelson,et al.  A randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated human immunodeficiency virus type 1-infected children. The CNAA3006 Study Team. , 2001, Pediatrics.

[88]  G. E. Pakes,et al.  Clinical Pharmacokinetics of Lamivudine , 1999, Clinical pharmacokinetics.

[89]  S. Steinberg,et al.  2',3'-didehydro-3'-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial. , 1993, The Journal of infectious diseases.

[90]  R. Husson,et al.  Retinal toxicity in human immunodeficiency virus-infected children treated with 2',3'-dideoxyinosine. , 1992, American journal of ophthalmology.

[91]  F. Balis,et al.  Clinical pharmacology of 2',3'-dideoxyinosine in human immunodeficiency virus-infected children. , 1992, The Journal of infectious diseases.

[92]  A. Tosti,et al.  Longitudinal melanonychia induced by 3'-azidodeoxythymidine. Report of 9 cases. , 1990, Dermatologica.